Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Centre Hospitalier Universitaire De Liège manages a patent portfolio in the Biotechnology & Pharmaceuticals technology area characterized by a singular focus. There is currently 1 pending office action under review. This matter is assigned to 1 distinct examiner, which simplifies the communication channel between the institution and the patent office for its active applications.
The prosecution is confined to 1 distinct art unit, indicating a specific technical focus within the broader biotechnology field. The busiest examiner for this portfolio is COUGHLIN, MATTHEW P, who is currently handling 1 busiest examiner pending office action. Because the total count of pending actions is 1, this examiner is the sole official reviewing the institution's current pending work. This arrangement means that the success of the current prosecution cycle depends entirely on the interactions within 1 distinct art unit and with this specific examiner.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| COUGHLIN, MATTHEW P | 1 | 71.3% | +12.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18261643 | NEW ANTIMICROBIAL AND ANTITHROMBOGENIC MEDICAL DEVICE | COUGHLIN, MATTHEW P | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18261643 | NEW ANTIMICROBIAL AND ANTITHROMBOGENIC MEDICAL DEVICE | COUGHLIN, MATTHEW P | — |
| Art Unit | Apps |
|---|---|
| 1626 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18261643 | NEW ANTIMICROBIAL AND ANTITHROMBOGENIC MEDICAL DEVICE | COUGHLIN, MATTHEW P | 1626 | §102§103§112 | Non-Final OA | — | Pending | Jul 14, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialCentre Hospitalier Universitaire De Liège has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Matthew P Coughlin has the most, with 1 of Centre Hospitalier Universitaire De Liège's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
